Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Non-Current Assets: 2009-2024

Historic Non-Current Assets for Cumberland Pharmaceuticals (CPIX) over the last 16 years, with Dec 2024 value amounting to $39.1 million.

  • Cumberland Pharmaceuticals' Non-Current Assets fell 13.37% to $36.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $36.0 million, marking a year-over-year decrease of 13.37%. This contributed to the annual value of $39.1 million for FY2024, which is 15.05% down from last year.
  • According to the latest figures from FY2024, Cumberland Pharmaceuticals' Non-Current Assets is $39.1 million, which was down 15.05% from $46.1 million recorded in FY2023.
  • Cumberland Pharmaceuticals' 5-year Non-Current Assets high stood at $47.1 million for FY2022, and its period low was $38.8 million during FY2021.
  • For the 3-year period, Cumberland Pharmaceuticals' Non-Current Assets averaged around $44.1 million, with its median value being $46.1 million (2023).
  • Per our database at Business Quant, Cumberland Pharmaceuticals' Non-Current Assets fell by 16.61% in 2021 and then increased by 21.36% in 2022.
  • Cumberland Pharmaceuticals' Non-Current Assets (Yearly) stood at $46.5 million in 2020, then declined by 16.61% to $38.8 million in 2021, then grew by 21.36% to $47.1 million in 2022, then decreased by 2.11% to $46.1 million in 2023, then decreased by 15.05% to $39.1 million in 2024.